Skip to main content
Top

Open Access 27-06-2024 | Diabetes Therapy | Review

Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification

Authors: Martin Haluzik, Zoltan Taybani, Aleksandra Araszkiewicz, Anca Cerghizan, Boris Mankovsky, Agbaria Zuhdi, Maciej Malecki

Published in: Diabetes Therapy

Login to get access

Abstract

The management of type 2 diabetes (T2D) often necessitates treatment intensification, and sometimes simplification to achieve glycaemic targets and mitigate complications. This expert opinion paper evaluates the use and positioning of the fixed-ratio combinations (FRCs) of basal insulin (BI) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in optimising T2D management. On the basis of the evidence presented and discussions, these FRCs offer a promising approach for both treatment intensification and simplification in people with suboptimal glucose control despite receiving various therapies. In treatment intensification, FRCs provide a synergistic effect by addressing multiple pathophysiological defects contributing to hyperglycaemia. These FRCs effectively control both fasting and postprandial glucose (PPG) excursions, offering significantly improved glycaemic control with a lower hypoglycaemia risk and weight neutrality compared to traditional or complex insulin regimens. Moreover, the reduced injection frequency (once daily) and flexibility in the dosing schedule (with any major meal of the day) help mitigate patient resistance to insulin initiation or titration. This further reduces treatment burden, facilitating treatment adherence and enhancing patient convenience. These key benefits of FRCs over complex insulin regimens play a crucial role in long-term glycaemic management and overall treatment outcomes. Hence, the timely use of FRCs in the treatment algorithm for people with T2D represents a valuable strategy for optimising glycaemic control, addressing treatment barriers and enhancing patient-reported outcomes.
Literature
1.
go back to reference Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11.PubMedPubMedCentralCrossRef Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11.PubMedPubMedCentralCrossRef
2.
go back to reference International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.
3.
go back to reference Boeder S, Matamoros D, Mansy C. Practical guidance for healthcare providers on collaborating with people with type 2 diabetes: advancing treatment and initiating injectable therapy. Diabetes Ther. 2023;14(2):425–46.PubMedCrossRef Boeder S, Matamoros D, Mansy C. Practical guidance for healthcare providers on collaborating with people with type 2 diabetes: advancing treatment and initiating injectable therapy. Diabetes Ther. 2023;14(2):425–46.PubMedCrossRef
4.
go back to reference ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.PubMedCrossRef ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.PubMedCrossRef
5.
go back to reference Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update. Endocr Pract. 2023;29(5):305–40.PubMedCrossRef Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update. Endocr Pract. 2023;29(5):305–40.PubMedCrossRef
6.
go back to reference Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–21.PubMedCrossRef Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–21.PubMedCrossRef
7.
go back to reference GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–34.CrossRef GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–34.CrossRef
8.
go back to reference Skyler JS. Effects of glycemic control on diabetes complications and on the prevention of diabetes. Clin Diabetes. 2004;22:162–6.CrossRef Skyler JS. Effects of glycemic control on diabetes complications and on the prevention of diabetes. Clin Diabetes. 2004;22:162–6.CrossRef
9.
go back to reference Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.PubMedPubMedCentralCrossRef Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.PubMedPubMedCentralCrossRef
10.
go back to reference Rattelman CR, Ciemins EL, Stempniewicz N, Mocarski M, Ganguly R, Cuddeback JK. A retrospective analysis of therapeutic inertia in type 2 diabetes management across a diverse population of health care organizations in the USA. Diabetes Ther. 2021;12(2):581–94.PubMedPubMedCentralCrossRef Rattelman CR, Ciemins EL, Stempniewicz N, Mocarski M, Ganguly R, Cuddeback JK. A retrospective analysis of therapeutic inertia in type 2 diabetes management across a diverse population of health care organizations in the USA. Diabetes Ther. 2021;12(2):581–94.PubMedPubMedCentralCrossRef
11.
go back to reference Gabbay RA, Kendall D, Beebe C, et al. Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. Clin Diabetes. 2020;38(4):371–81.PubMedPubMedCentralCrossRef Gabbay RA, Kendall D, Beebe C, et al. Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. Clin Diabetes. 2020;38(4):371–81.PubMedPubMedCentralCrossRef
13.
go back to reference Jude EB, Malecki MT, Gomez Huelgas R, et al. Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes. Diabetes Ther. 2022;13(4):619–34.PubMedPubMedCentralCrossRef Jude EB, Malecki MT, Gomez Huelgas R, et al. Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes. Diabetes Ther. 2022;13(4):619–34.PubMedPubMedCentralCrossRef
14.
go back to reference Karam SL, Dendy J, Polu S, Blonde L. Overview of therapeutic inertia in diabetes: prevalence, causes, and consequences. Diabetes Spectr. 2020;33(1):8–15.PubMedPubMedCentralCrossRef Karam SL, Dendy J, Polu S, Blonde L. Overview of therapeutic inertia in diabetes: prevalence, causes, and consequences. Diabetes Spectr. 2020;33(1):8–15.PubMedPubMedCentralCrossRef
15.
go back to reference Zhu NA, Harris SB. Therapeutic inertia in people with type 2 diabetes in primary care: a challenge that just won’t go away. Diabetes Spectr. 2020;33(1):44–9.PubMedPubMedCentralCrossRef Zhu NA, Harris SB. Therapeutic inertia in people with type 2 diabetes in primary care: a challenge that just won’t go away. Diabetes Spectr. 2020;33(1):44–9.PubMedPubMedCentralCrossRef
16.
go back to reference Blonde L, Anderson JE, Chava P, Dendy JA. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):793–804.PubMedCrossRef Blonde L, Anderson JE, Chava P, Dendy JA. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):793–804.PubMedCrossRef
17.
go back to reference Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93.PubMedCrossRef Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93.PubMedCrossRef
18.
go back to reference Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926–33.PubMedCrossRef Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926–33.PubMedCrossRef
19.
go back to reference Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972–80.PubMedCrossRef Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972–80.PubMedCrossRef
20.
go back to reference Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–35.PubMedCrossRef Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–35.PubMedCrossRef
21.
go back to reference Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021;44(10):2361–70.PubMedPubMedCentralCrossRef Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021;44(10):2361–70.PubMedPubMedCentralCrossRef
22.
go back to reference Miller E, Doshi A, Gron R, et al. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. Diabetes Obes Metab. 2019;21(12):2643–50.PubMedPubMedCentralCrossRef Miller E, Doshi A, Gron R, et al. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. Diabetes Obes Metab. 2019;21(12):2643–50.PubMedPubMedCentralCrossRef
23.
go back to reference Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial. Diabetes Care. 2019;42(11):2108–16.PubMedCrossRef Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial. Diabetes Care. 2019;42(11):2108–16.PubMedCrossRef
24.
go back to reference Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 2017;8(1):101–14.PubMedCrossRef Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther. 2017;8(1):101–14.PubMedCrossRef
25.
go back to reference Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189–96.PubMedCrossRef Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189–96.PubMedCrossRef
26.
go back to reference Lingvay I, Perez Manghi F, Garcia-Hernandez P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315(9):898–907.PubMedCrossRef Lingvay I, Perez Manghi F, Garcia-Hernandez P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315(9):898–907.PubMedCrossRef
27.
go back to reference Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017;19(6):858–65.PubMedPubMedCentralCrossRef Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017;19(6):858–65.PubMedPubMedCentralCrossRef
28.
go back to reference Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009–16.PubMedCrossRef Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009–16.PubMedCrossRef
29.
go back to reference Aroda VR, Gonzalez-Galvez G, Gron R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):596–605.PubMedCrossRef Aroda VR, Gonzalez-Galvez G, Gron R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):596–605.PubMedCrossRef
30.
go back to reference Philis-Tsimikas A, Billings LK, Busch R, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(6):1399–408.PubMedPubMedCentralCrossRef Philis-Tsimikas A, Billings LK, Busch R, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(6):1399–408.PubMedPubMedCentralCrossRef
31.
32.
go back to reference Rayner CK, Wu T, Aroda VR, et al. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab. 2021;23(1):136–46.PubMedCrossRef Rayner CK, Wu T, Aroda VR, et al. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab. 2021;23(1):136–46.PubMedCrossRef
33.
go back to reference Home P, Blonde L, Kalra S, et al. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: a systematic review and Bayesian network meta-analysis. Diabetes Obes Metab. 2020;22(11):2179–88.PubMedCrossRef Home P, Blonde L, Kalra S, et al. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: a systematic review and Bayesian network meta-analysis. Diabetes Obes Metab. 2020;22(11):2179–88.PubMedCrossRef
34.
go back to reference Dekic D, Bojic M, Janez A, et al. Effectiveness and safety of iGlarLixi in people with type 2 diabetes in Adriatic Region countries: ENSURE-ADR, a real-world study. Diabetes Ther. 2023;14(7):1217–29.PubMedPubMedCentralCrossRef Dekic D, Bojic M, Janez A, et al. Effectiveness and safety of iGlarLixi in people with type 2 diabetes in Adriatic Region countries: ENSURE-ADR, a real-world study. Diabetes Ther. 2023;14(7):1217–29.PubMedPubMedCentralCrossRef
35.
go back to reference Hassanein M, Malek R, Shaltout I, et al. Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: the SoliRam observational study. Diabetes Metab Syndr. 2023;17(2): 102707.PubMedCrossRef Hassanein M, Malek R, Shaltout I, et al. Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: the SoliRam observational study. Diabetes Metab Syndr. 2023;17(2): 102707.PubMedCrossRef
36.
go back to reference Watada H, Ross Agner BF, Doshi A, Bardtrum L, Ranthe MF, Billings LK. IDegLira improves glycemic control in Japanese patients with uncontrolled type 2 diabetes on premixed insulin therapy. Diabetes Ther. 2020;11(1):331–9.PubMedCrossRef Watada H, Ross Agner BF, Doshi A, Bardtrum L, Ranthe MF, Billings LK. IDegLira improves glycemic control in Japanese patients with uncontrolled type 2 diabetes on premixed insulin therapy. Diabetes Ther. 2020;11(1):331–9.PubMedCrossRef
37.
go back to reference Szepkuti S, Bandur S, Kovacs G, et al. Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study. BMC Endocr Disord. 2022;22(1):229.PubMedPubMedCentralCrossRef Szepkuti S, Bandur S, Kovacs G, et al. Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study. BMC Endocr Disord. 2022;22(1):229.PubMedPubMedCentralCrossRef
38.
go back to reference Pogach L, Aron D. Balancing hypoglycemia and glycemic control: a public health approach for insulin safety. JAMA. 2010;303(20):2076–7.PubMedCrossRef Pogach L, Aron D. Balancing hypoglycemia and glycemic control: a public health approach for insulin safety. JAMA. 2010;303(20):2076–7.PubMedCrossRef
39.
go back to reference Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2017;40(4):614–24.PubMedCrossRef Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2017;40(4):614–24.PubMedCrossRef
40.
go back to reference Maiorino MI, Chiodini P, Bellastella G, et al. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2019;154:101–15.PubMedCrossRef Maiorino MI, Chiodini P, Bellastella G, et al. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2019;154:101–15.PubMedCrossRef
41.
go back to reference Cimmaruta D, Maiorino MI, Scavone C, et al. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opin Drug Saf. 2016;15(Suppl 2):77–83.PubMedCrossRef Cimmaruta D, Maiorino MI, Scavone C, et al. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opin Drug Saf. 2016;15(Suppl 2):77–83.PubMedCrossRef
43.
go back to reference Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–9.PubMedPubMedCentralCrossRef Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18(4):401–9.PubMedPubMedCentralCrossRef
44.
go back to reference Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–75.PubMedCrossRef Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–75.PubMedCrossRef
45.
go back to reference Spain CV, Wright JJ, Hahn RM, Wivel A, Martin AA. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653-64.e1.PubMedCrossRef Spain CV, Wright JJ, Hahn RM, Wivel A, Martin AA. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653-64.e1.PubMedCrossRef
46.
go back to reference Gonzalez JS, Tanenbaum ML, Commissariat PV. Psychosocial factors in medication adherence and diabetes self-management: implications for research and practice. Am Psychol. 2016;71(7):539–51.PubMedPubMedCentralCrossRef Gonzalez JS, Tanenbaum ML, Commissariat PV. Psychosocial factors in medication adherence and diabetes self-management: implications for research and practice. Am Psychol. 2016;71(7):539–51.PubMedPubMedCentralCrossRef
47.
go back to reference Bohm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS One. 2021;16(5): e0250993.PubMedPubMedCentralCrossRef Bohm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS One. 2021;16(5): e0250993.PubMedPubMedCentralCrossRef
48.
go back to reference Naing S, Ramesh G, Garcha J, Poliyedath A, Khandelwal S, Mills PK. Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled type 2 diabetes on advanced insulin therapy? Endocrinol Diabetes Metab. 2021;4(2): e00204.PubMedCrossRef Naing S, Ramesh G, Garcha J, Poliyedath A, Khandelwal S, Mills PK. Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled type 2 diabetes on advanced insulin therapy? Endocrinol Diabetes Metab. 2021;4(2): e00204.PubMedCrossRef
49.
go back to reference Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2020 Executive Summary. Endocr Pract. 2020;26(1):107–39.PubMedCrossRef Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2020 Executive Summary. Endocr Pract. 2020;26(1):107–39.PubMedCrossRef
50.
go back to reference Polonsky WH, Giorgino F, Rosenstock J, et al. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes Obes Metab. 2022;24(12):2364–72.PubMedPubMedCentralCrossRef Polonsky WH, Giorgino F, Rosenstock J, et al. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes Obes Metab. 2022;24(12):2364–72.PubMedPubMedCentralCrossRef
51.
go back to reference Tabak AG, Anderson J, Aschner P, et al. Efficacy and safety of iGlarLixi, fixed-ratio combination of insulin glargine and lixisenatide, compared with basal-bolus regimen in patients with type 2 diabetes: propensity score matched analysis. Diabetes Ther. 2020;11(1):305–18.PubMedCrossRef Tabak AG, Anderson J, Aschner P, et al. Efficacy and safety of iGlarLixi, fixed-ratio combination of insulin glargine and lixisenatide, compared with basal-bolus regimen in patients with type 2 diabetes: propensity score matched analysis. Diabetes Ther. 2020;11(1):305–18.PubMedCrossRef
52.
go back to reference McCrimmon RJ, Cheng AYY, Galstyan G, et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: the SoliSimplify real-world study. Diabetes Obes Metab. 2023;25(1):68–77.PubMedCrossRef McCrimmon RJ, Cheng AYY, Galstyan G, et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: the SoliSimplify real-world study. Diabetes Obes Metab. 2023;25(1):68–77.PubMedCrossRef
53.
go back to reference Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y. Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study. Diabetes Ther. 2023;14(4):671–89.PubMedPubMedCentralCrossRef Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y. Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study. Diabetes Ther. 2023;14(4):671–89.PubMedPubMedCentralCrossRef
54.
go back to reference Persano M, Nollino L, Sambataro M, et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Eur Rev Med Pharmacol Sci. 2021;25(2):923–31.PubMed Persano M, Nollino L, Sambataro M, et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Eur Rev Med Pharmacol Sci. 2021;25(2):923–31.PubMed
55.
go back to reference Price H, Bluher M, Prager R, et al. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab. 2018;20(4):954–62.PubMedPubMedCentralCrossRef Price H, Bluher M, Prager R, et al. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab. 2018;20(4):954–62.PubMedPubMedCentralCrossRef
56.
go back to reference Taybani ZJ, Botyik B, Gyimesi A, Katko M, Varkonyi T. One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes. Endocrinol Diabetes Metab. 2023;6(1): e390.PubMedCrossRef Taybani ZJ, Botyik B, Gyimesi A, Katko M, Varkonyi T. One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes. Endocrinol Diabetes Metab. 2023;6(1): e390.PubMedCrossRef
57.
go back to reference Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial. Diabetes Care. 2021;44(6):1353–60.PubMedPubMedCentralCrossRef Giugliano D, Longo M, Caruso P, et al. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial. Diabetes Care. 2021;44(6):1353–60.PubMedPubMedCentralCrossRef
58.
go back to reference Giugliano D, Longo M, Scappaticcio L, et al. BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes. Endocrine. 2024;83(2):399–404.PubMedCrossRef Giugliano D, Longo M, Scappaticcio L, et al. BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes. Endocrine. 2024;83(2):399–404.PubMedCrossRef
Metadata
Title
Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification
Authors
Martin Haluzik
Zoltan Taybani
Aleksandra Araszkiewicz
Anca Cerghizan
Boris Mankovsky
Agbaria Zuhdi
Maciej Malecki
Publication date
27-06-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01610-w
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare